Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genomic mapping has driven the classification of glioblastoma into distinct molecular subclasses, but mechanisms that regulate tumor subclass phenotypes are only now emerging.In this issue of Cancer Cell, Lu et al. describe a phenotypic switch from PDGFRA-enriched "proneural" to EGFR-enriched "classical" features in glioblastoma upon ablation of Olig2.
|
27165737 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Through double-immunohistochemical staining for platelet-derived growth factor receptor α (PDGFRα) and glial fibrillary acidic protein (GFAP), this study explored the intercase variability among 45 human GBM samples regarding density of GFAP+ peritumoral astrocytes and a subset of GFAP+ peritumoral astrocyte-like cells also expressing PDGFRα.
|
31769546 |
2020 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A younger age at diagnosis and better clinical outcome in glioblastoma patients is only seen when PDGFRA and KIT are co-amplified.
|
23990986 |
2013 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, forced expression of miR-129-2 repressed the expression of major oncogenic genes such as PDGFRa and Foxp1 in GBMs.
|
26320507 |
2015 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We showed that machine-based classification of GBMs with high oligodendroglioma component uncovered a set of tumors with strong associations with PDGFRA amplification, proneural transcriptional class, and expression of the oligodendrocyte signature genes MBP, HOXD1, PLP1, MOBP and PDGFRA.
|
24236209 |
2013 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
|
31232447 |
2019 |
Glioblastoma
|
0.400 |
CausalMutation
|
disease |
CGI |
|
|
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Haplotype-specific expression of the human PDGFRA gene correlates with the risk of glioblastomas.
|
18464291 |
2008 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.
|
30082792 |
2018 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although it is known that oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive.
|
22080864 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
KIT was amplified in 47% and VEGFR2 in 39% of the glioblastomas, respectively, and PDGFRA in 29%.
|
16021678 |
2005 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A common theme in glioblastoma is the amplification of genes that code for growth factor receptors of the protein-tyrosine kinase family (epidermal growth factor receptor, platelet-derived growth factor receptor-alpha, met).
|
7654823 |
1995 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS.
|
27844311 |
2017 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The extrachromosomal nature of ALEMs explains the observed drastic changes in the amounts of mutated oncogenes (like EGFR or PDGFRA) in glioblastoma in response to environmental changes.
|
25471132 |
2014 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, ectopic expression of PDGFRα, NOS2, or ID4 activated the PDGF-NO-ID4-signaling circuit and enhanced the self-renewal of GBM cell lines.
|
28327358 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Four glioblastomas showed markedly increased PDGFRA mRNA expression due to PDGFRA gene amplification.
|
14730454 |
2004 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Surprisingly, we observed the induction of anti-apoptotic proteins and compensatory oncogenic signals such as EDN1, EDNRB, PRKCB1, PDGF-C and PDGF-D. To conclude, we hypothesize that the newly discovered PDGFRα/Stat3/Rb1 regulatory axis might represent a potential therapeutic target for GBM treatment.
|
27344175 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of PDGF system components, particularly the alpha subtype receptor (PDGFRA), is common in glial tumors, and PDGFRA gene amplification has been reported in glioblastomas.
|
10850862 |
2000 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further analysis, including whole exome sequencing, revealed missense mutations or complex gene fusion events in PDGFRA with augmented expression in the secondary glioblastomas after radiotherapy, implicating PDGFRA as a putative driver in the development of secondary glioblastomas after treatment exposure.
|
29644394 |
2018 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.
|
16186508 |
2005 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
|
22323597 |
2012 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
No significant difference was observed in the frequency of amplification of these genes in primary and secondary glioblastomas or in glioblastomas with and without IDH1 mutations, suggesting that amplification of PDGFRA, KIT and KDR may be implicated in the pathogenesis of a small fraction of both subtypes of glioblastoma.
|
21382095 |
2011 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PDGFRA amplification was more common in cases with GBM than with PNET morphology (36 vs. 5 %, respectively), while CCND2 amplifications showed the opposite trend (5 vs. 27 %).
|
26482474 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastomas with a proneural expression signature are characterized by frequent IDH1 mutations (i.e. genetic hallmarks of secondary glioblastomas) and PDGFRA (platelet-derived growth factor receptor-α) amplification.
|
23242283 |
2013 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that PDGFRα is expressed only in a subset of GBMs, while PDGFRβ is more commonly expressed in tumors but is preferentially expressed by self-renewing tumorigenic GBM stem cells (GSCs).
|
22661233 |
2012 |